Gómez-Martínez G, Maldonado-Almaraz B, Martínez-Delgado IA

Language: Spanish
References: 20
Page: 125-131
PDF size: 184.96 Kb.

ABSTRACT

Objective: To describe echocardiographic abnormalities in patients with acromegaly. Study design: Observational, prospective, cross-sectional. Material and methods: Twenty-two patients › 18 years of age with a diagnosis of GH-secreting pituitary adenoma were assessed using echocardiogram. Results: Six microadenomas and 16 macroadenomas were demonstrated. There were 15 females and seven males (average age 47 years; range: 22–76). Twenty were operated (90%). Biochemical disease status was as follows: 17 active, four cured and one controlled with OCT LAR. Time of evolution of signs and symptoms of acromegaly was 7.1 years (range: 1-30). Average age at diagnosis was 40 years (range: 19-60). The most representative echographic results were concentric left ventricular hypertrophy (six patients, four with systemic arterial hypertension, SAH) and mild dilatation (one patient with SAH). Systolic dysfunction was shown in one asymptomatic patient (fractional shortening ‹ 29% and FEVI 45%). Ten patients had diastolic dysfunction. Valvular involvement included mild mitral insufficiency (five patients) and mild tricuspid insufficiency (seven patients). Expanded left atrium was demonstrated in five patients (three with SAH). In two patients, three chambers were affected and four chambers in one patient. One patient had thickened intraventricular septum without hypertension. Conclusions: Cardiac abnormalities in acromegaly are considered the major determinant of mortality and reduced life expectancy. Expansion of cardiac cavities (50%), diastolic dysfunction (45%), valvulopathy (31%) and left ventricular hypertrophy (27%) were the most frequent findings, demonstrating the importance of early detection and control of acromegaly to avoid cardiovascular repercussions.

REFERENCES

1. Holdaway IM, Rajasoorya C: Epidemiology of acromegaly. Pituitary. 1999; 2: 29-41.

2. Colao A, Ferone D, Marzulio P et al: Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Reviews. 2004; 25: 102-105.

3. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML; AACE Acromegaly Guidelines Task Force: AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment ofacromegaly. Endocr Pract. 2004 10: 213-25.

4. Melmed S, Colao A, Barkan A et al: Guidelines for acromegaly management: an update. J Clin Endocrinol Met. 2009; 94: 1509-1517.

5. Melmed S: Acromegaly. N Eng J Med. 2006; 355: 2558-73.

6. Pereira AM, van Thiel SW, Lindner JR et al: Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004; 89: 71-5.

7. Huchard H: Anatomie pathologique, lesions et trouble cardiovasculaires de l’ acromegalie. J Practiciens. 1895; 9: 249-250.

8. Hunter JJ, Chien KR: Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999; 341: 1276-1283.

9. Thuesen L, Christnsen SE, Weeke J et al: A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand. 1988; 223: 337-343.

10. Hejtmancik MR, Bradfield JY, Herrmann GR: Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med. 1951; 34: 1445-1456.

11. Lie JT, Grossman SJ: Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J. 1980; 100: 41-52.

12. Colao A, Merola B, Ferrone D et al: Acromegaly. J Clin Endocrinol Metab. 1997; 82: 2777-2781.

13. Minniti G, Jaffrain-Rea, Moroni C et al: Echocardiographic evidence for a direct effect of GH/IGF-1 hypersecretion on cardiac mass and function in young acromegalics. J Clin Endocrinol Metab. 1998; 49: 101-106.

14. Colao A, Spinelli L, Cuocolo A et al: Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab. 2002; 87: 3097-3104.

15. Ferrari AU: Modifications of the cardiovascular system with aging. Am J Geriatr Cardiol. 2002; 11: 30-33.

16. Consenso Nacional de Acromegalia: Guía para su diagnóstico, tratamiento y seguimiento. Revista de Endocrinología y Nutrición. 2004; 12: S63-S72.

17. Balderrama-Soto A, Vergara-López A, Guillén-González MA, Joya-Galeana J, Harol Ixcamparij-Rosales C: Características ecocardiográficas de los pacientes con acromegalia del Centro Médico Nacional 20 de Noviembre. Revista de Endocrinología y Nutrición. 2011; 19: 7-11.

18. Marín OF, Picó AM, Martínez JG, Domínguez JR, Alfayete R, Sogorb F: Alteraciones cardiológicas en la acromegalia. Estudio de 27 pacientes. Med Clin (Barc). 1996; 107: 326-330.

19. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A: Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000; 85: 193-199.

20. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P: Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007; 92: 1743-1747.